tradingkey.logo

Eli Lilly and Co

LLY
1058.180USD
+37.340+3.66%
收盤 02/06, 16:00美東報價延遲15分鐘
1.00T總市值
46.11本益比TTM

Eli Lilly and Co

1058.180
+37.340+3.66%

關於 Eli Lilly and Co 公司

禮來公司是一家制藥公司。該公司在人類藥品領域發現、開發、製造和銷售產品。其糖尿病、肥胖症和其他心臟代謝產品包括 Basaglar、Humalog、Mounjaro、Trulicity 和 Zepbound。其腫瘤產品包括 Alimta、Retevmo、Tyvyt 和 Verzenio。其免疫學產品包括 Ebglyss、Olumiant、Omvoh 和 Taltz。其神經科學產品包括 Cymbalta 和 Emgality。其其他產品和療法包括 Cialis 和 Forteo。該公司通過位於美國(包括波多黎各)以及歐洲和亞洲的工廠生產和分銷其產品。該公司通過其子公司 POINT Biopharma Global Inc. 從事放射性藥物的發現、開發和製造,以及臨牀和臨牀前放射性配體療法。該公司還在開發用於治療炎症性腸病 (IBD) 的 α4β7 整合素口服小分子抑制劑 (稱爲 MORF-057)。

Eli Lilly and Co簡介

公司代碼LLY
公司名稱Eli Lilly and Co
上市日期Jul 09, 1970
CEORicks (David A)
員工數量47000
證券類型Ordinary Share
年結日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編46285
電話13172762000
網址https://www.lilly.com/
公司代碼LLY
上市日期Jul 09, 1970
CEORicks (David A)

Eli Lilly and Co公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.59K
+10.00%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+8641.00%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
56.30K
+2178.00%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
41.71K
+1981.00%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
29.41K
+3747.00%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.14K
+1882.00%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+215.00%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
21.80K
+2078.00%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+715.00%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
11.43K
+1585.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.59K
+10.00%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+8641.00%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
56.30K
+2178.00%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
41.71K
+1981.00%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
29.41K
+3747.00%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.14K
+1882.00%

收入明細

單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
其他
3.91B
22.23%
地區USD
名稱
營收
佔比
U.S.
11.30B
64.20%
Europe
3.50B
19.87%
Other foreign countries
1.69B
9.59%
China
560.40M
3.18%
Japan
554.70M
3.15%
業務
地區
業務USD
名稱
營收
佔比
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
其他
3.91B
22.23%

股東統計

更新時間: 11月12日 週三
更新時間: 11月12日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Lilly Endowment, Inc.
9.72%
The Vanguard Group, Inc.
8.63%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.14%
持股股東
持股股東
佔比
Lilly Endowment, Inc.
9.72%
The Vanguard Group, Inc.
8.63%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
其他
68.14%
股東類型
持股股東
佔比
Investment Advisor
45.56%
Investment Advisor/Hedge Fund
18.81%
Foundation
9.72%
Research Firm
2.04%
Pension Fund
1.95%
Bank and Trust
1.76%
Insurance Company
1.47%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
其他
16.66%

機構持股

更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
5995
789.04M
83.45%
-5.66M
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Lilly Endowment, Inc.
92.19M
9.75%
-6.46K
-0.01%
Dec 29, 2025
The Vanguard Group, Inc.
80.59M
8.52%
+541.95K
+0.68%
Sep 30, 2025
PNC Investments LLC
51.15M
5.41%
+70.46K
+0.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
41.90M
4.43%
+599.55K
+1.45%
Sep 30, 2025
State Street Investment Management (US)
34.73M
3.67%
+219.59K
+0.64%
Sep 30, 2025
Capital Research Global Investors
25.09M
2.65%
+4.33M
+20.87%
Sep 30, 2025
Fidelity Management & Research Company LLC
22.69M
2.4%
-1.67M
-6.86%
Sep 30, 2025
Geode Capital Management, L.L.C.
19.82M
2.1%
+1.69M
+9.32%
Sep 30, 2025
Capital World Investors
14.97M
1.58%
-2.66M
-15.11%
Sep 30, 2025
Wellington Management Company, LLP
14.56M
1.54%
+574.23K
+4.10%
Sep 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
查看更多
VanEck Pharmaceutical ETF
佔比47.56%
iShares U.S. Pharmaceuticals ETF
佔比25.23%
Harbor Health Care ETF
佔比18.24%
Roundhill GLP-1 & Weight Loss ETF
佔比16.7%
Health Care Select Sector SPDR Fund
佔比14.06%
Proshares Ultra Health Care
佔比13.57%
iShares U.S. Healthcare ETF
佔比13.54%
Amplify Weight Loss Drug & Treatment ETF
佔比11.93%
Fidelity MSCI Health Care Index ETF
佔比11.73%
Goldman Sachs Future Health Care Equity ETF
佔比10.84%

分紅派息

近5年累計派現 15.37B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Dec 08, 2025
LLY.NB Interim Cash Dividend of gross USD 1.73 paid on Mar 10, 2026 going ex on Feb 13, 2026
Feb 13, 2026
Mar 10, 2026
Feb 13, 2026
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
查看更多

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI